The biopharmaceutical company Amgen, which is based in Thousand Oaks, Calif., has pleaded guilty to a federal misdemeanor for misbranding its anemia drug and agreed to pay $762 million in fines and penalties, according to a Washington Post report.
The company agreed to pay $612 million in a civil settlement, a $14 million criminal forfeiture payment and a $136 million criminal fine, according to the report.
J&J to Pay $2.2B Settlement to End Risperdal Probes
Pfizer Reaches $60M Settlement Over Foreign Bribe Allegations
The company agreed to pay $612 million in a civil settlement, a $14 million criminal forfeiture payment and a $136 million criminal fine, according to the report.
More Articles on Pharmaceutical Settlements:
Johnson & Johnson to Pay $181M Settlement Over Risperdal MarketingJ&J to Pay $2.2B Settlement to End Risperdal Probes
Pfizer Reaches $60M Settlement Over Foreign Bribe Allegations